# Protagenic Therapeutics Inc. (PTIX)

Source: https://www.quantisnow.com/company/PTIX
Generated: 2026-11-12T22:04:18.725Z

- Ticker: PTIX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001022899
- Website: protagenic.com

## About

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

## Latest PTIX news and filings

- 2026-11-11 13:30 UTC [Market Insight] [Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder](https://www.quantisnow.com/insight/protagenic-therapeutics-announces-private-placement-of-up-to-5-million-6785292)
- 2026-11-06 19:28 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-protagenic-therapeutics-inc-6778628)
- 2026-11-06 19:15 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6778610)
- 2026-08-24 17:20 UTC [Insider Buy] [EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $13,000 worth of shares (20,000 units at $0.65), increasing direct ownership by 37% to 73,533 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-chair-principal-off-armen-garo-h-bought-13000-worth-6692477)
- 2026-08-21 00:20 UTC [Insider Buy] [EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $9,811 worth of shares (16,634 units at $0.59), increasing direct ownership by 45% to 53,533 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-chair-principal-off-armen-garo-h-bought-9811-worth-6690606)
- 2026-08-20 15:26 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6689781)
- 2026-08-20 13:23 UTC [Insider Buy] [EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $945 worth of shares (2,700 units at $0.35), increasing direct ownership by 8% to 36,899 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-chair-principal-off-armen-garo-h-bought-945-worth-6689710)
- 2026-08-20 12:30 UTC [Market Insight] [Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder](https://www.quantisnow.com/insight/protagenic-therapeutics-receives-fda-pre-ind-feedback-supporting-new-ind-for-6689545)
- 2026-08-19 20:28 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-protagenic-therapeutics-inc-6688506)
- 2026-08-14 19:20 UTC [SEC Form NT 10-Q filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-protagenic-therapeutics-inc-6682847)
- 2026-08-14 19:19 UTC [SEC Form 10-K] [SEC Form 10-K filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-protagenic-therapeutics-inc-6682845)
- 2026-08-12 22:51 UTC [Insider Buy] [EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $710 worth of shares (2,220 units at $0.32), increasing direct ownership by 7% to 34,199 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-chair-principal-off-armen-garo-h-bought-710-worth-6678793)
- 2026-08-10 14:17 UTC [Insider Buy] [EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $151 worth of shares (685 units at $0.22), increasing direct ownership by 2% to 31,979 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-chair-principal-off-armen-garo-h-bought-151-worth-6673173)
- 2026-08-07 00:29 UTC [Insider Buy] [EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $1,294 worth of shares (5,000 units at $0.26), increasing direct ownership by 19% to 31,294 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-chair-principal-off-armen-garo-h-bought-1294-worth-6670300)
- 2026-08-03 21:29 UTC [Insider Buy] [EXEC. CHAIR & PRINCIPAL OFF. Armen Garo H bought $4,806 worth of shares (26,291 units at $0.18) (SEC Form 4)](https://www.quantisnow.com/insight/exec-chair-principal-off-armen-garo-h-bought-4806-worth-6660415)
- 2026-06-30 15:00 UTC [SEC Form NT 10-K filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-protagenic-therapeutics-inc-6620420)
- 2026-06-30 12:30 UTC [Market Insight] [Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model](https://www.quantisnow.com/insight/protagenic-therapeutics-lead-candidate-pt00114-attenuated-chronic-stress-responses-in-6620125)
- 2026-05-19 12:15 UTC [Market Insight] [Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner](https://www.quantisnow.com/insight/protagenic-therapeutics-engages-floyd-regulatory-strategic-consulting-as-regulatory-affairs-6561765)
- 2026-04-23 12:15 UTC [Market Insight] [Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114](https://www.quantisnow.com/insight/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-6511754)
- 2026-03-17 12:00 UTC [Market Insight] [Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114](https://www.quantisnow.com/insight/protagenic-therapeutics-completes-phytanix-separation-strengthens-balance-sheet-and-repositions-6451172)
- 2026-03-10 12:00 UTC [Market Insight] [Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market](https://www.quantisnow.com/insight/protagenic-therapeutics-upgrades-from-otc-pink-to-otcqb-venture-market-6438674)
- 2026-03-09 11:46 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-protagenic-therapeutics-inc-6436232)
- 2026-03-03 02:27 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-leadership-update-6423597)
- 2026-02-24 01:49 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6408526)
- 2026-02-18 11:48 UTC [SEC Form NT 10-Q filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-protagenic-therapeutics-inc-6398069)
- 2026-01-05 12:45 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6333131)
- 2025-12-09 13:46 UTC [Market Insight] [Results from Phase 1 Multiple-Dose Study of PT00114](https://www.quantisnow.com/insight/results-from-phase-1-multiple-dose-study-of-pt00114-6308208)
- 2025-12-05 21:52 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-protagenic-therapeutics-inc-6305344)
- 2025-11-27 08:45 UTC [Market Insight] [Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice](https://www.quantisnow.com/insight/protagenic-therapeutics-announces-receipt-of-nasdaq-non-compliance-notice-6295846)
- 2025-11-26 22:26 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-protagenic-therapeutics-inc-6295633)
- 2025-11-26 21:18 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6295257)
- 2025-11-14 22:04 UTC [SEC Form NT 10-Q filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-protagenic-therapeutics-inc-6281329)
- 2025-11-13 13:22 UTC [Market Insight] [Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study](https://www.quantisnow.com/insight/protagenic-therapeutics-announces-completion-of-enrollment-and-dosing-in-phase-6276360)
- 2025-11-05 21:21 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-leadership-update-6262770)
- 2025-10-31 21:08 UTC [SEC Form 8-K] [Protagenic Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protagenic-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6254931)
- 2025-10-24 21:29 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-protagenic-therapeutics-inc-6244906)
- 2025-10-24 17:40 UTC [SEC Form 3] [New insider Evans Barrett claimed ownership of 787 units of Preferred Stock Series C, claimed ownership of 131,034 units of Preferred Stock Series C-1, claimed ownership of 6,498 units of Preferred Stock Series D and claimed ownership of 16,233 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-evans-barrett-claimed-ownership-of-787-units-of-6244396)
- 2025-09-17 16:21 UTC [SEC Form 8-K] [Amendment: Protagenic Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-protagenic-therapeutics-inc-filed-sec-form-8-k-financial-statements-6203720)
- 2025-09-10 20:06 UTC [SEC Form 10-QT filed by Protagenic Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-qt-filed-by-protagenic-therapeutics-inc-6196525)
- 2025-08-27 22:28 UTC [SEC Form 8-K] [Amendment: Protagenic Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-protagenic-therapeutics-inc-filed-sec-form-8-k-financial-statements-6181477)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PTIX
- Earnings history: https://www.quantisnow.com/earnings/PTIX
- Dividend history: https://www.quantisnow.com/dividends/PTIX
- Insider transactions: https://www.quantisnow.com/insiders/PTIX
- Options chain: https://www.quantisnow.com/options/PTIX
- SEC 8-K filings only: https://www.quantisnow.com/company/PTIX/8-k
- RSS and alerts for PTIX: https://www.quantisnow.com/docs/rss-feeds.md